Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an
Acrylamides
Adenocarcinoma of Lung
/ drug therapy
Aniline Compounds
Carcinoma, Non-Small-Cell Lung
/ genetics
Drug Resistance, Neoplasm
/ genetics
ErbB Receptors
/ genetics
Humans
Indoles
Lung Neoplasms
/ drug therapy
Mutation
/ genetics
Protein Kinase Inhibitors
/ pharmacology
Proto-Oncogene Proteins p21(ras)
/ genetics
Pyrimidines
EGFR
KRAS
drug resistance
osimertinib
third-generation epidermal growth factor receptor tyrosine kinase inhibitor
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
14 07 2022
14 07 2022
Historique:
received:
26
05
2022
revised:
09
07
2022
accepted:
11
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
29
7
2022
Statut:
epublish
Résumé
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is used as a first-line treatment for patients with EGFR-mutant non-small cell lung cancer (NSCLC). However, the mechanisms underlying its anticancer activity, particularly the subsequent development of acquired resistance, are unclear. Herein, we investigated the mechanisms underlying the development of osimertinib resistance by treating NSCLC PC-9 cells (harboring an EGFR-activating mutation) with osimertinib, thereby developing five resistant cell lines, i.e., AZDR3, AZDR6, AZDR9, AZDR11, and AZDR14. The amplification of wild-type
Identifiants
pubmed: 35883645
pii: cells11142201
doi: 10.3390/cells11142201
pmc: PMC9319811
pii:
doi:
Substances chimiques
Acrylamides
0
Aniline Compounds
0
Indoles
0
Protein Kinase Inhibitors
0
Pyrimidines
0
osimertinib
3C06JJ0Z2O
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Clin Cancer Res. 2017 Nov 1;23(21):6567-6579
pubmed: 28765329
Oncogene. 2007 Feb 26;26(9):1324-37
pubmed: 17322918
Cell Rep Med. 2020 Apr 21;1(1):
pubmed: 32483558
Transl Oncol. 2019 May;12(5):705-713
pubmed: 30856555
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
Cancer Res. 2004 Dec 15;64(24):8816-20
pubmed: 15604238
Cancer Res. 2013 Jan 15;73(2):834-43
pubmed: 23172312
Mol Cancer Ther. 2014 Feb;13(2):399-409
pubmed: 24296829
Oncogene. 2008 Jun 5;27(25):3508-15
pubmed: 18223690
Trends Cell Biol. 2003 Mar;13(3):122-30
pubmed: 12628344
J Biol Chem. 2002 Mar 15;277(11):9498-504
pubmed: 11779868
J Thorac Oncol. 2014 Feb;9(2):154-62
pubmed: 24419411
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Trends Biochem Sci. 2003 Jun;28(6):284-93
pubmed: 12826400
Nature. 2000 Oct 12;407(6805):770-6
pubmed: 11048727
Clin Cancer Res. 2016 Oct 1;22(19):4837-4847
pubmed: 27252416
Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8872-9
pubmed: 16361577
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
N Engl J Med. 2009 Sep 3;361(10):958-67
pubmed: 19692684
J Biol Chem. 1999 Jan 8;274(2):1156-63
pubmed: 9873064
Cell. 1996 Nov 15;87(4):629-38
pubmed: 8929532
J Biol Chem. 2020 May 1;295(18):6187-6201
pubmed: 32188694
Mol Cancer Ther. 2016 Dec;15(12):3040-3054
pubmed: 27612490
J Med Chem. 2020 Nov 25;63(22):13578-13594
pubmed: 32910655
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Mol Cancer Ther. 2019 Jan;18(1):112-126
pubmed: 30322949
Mol Cancer Res. 2020 Apr;18(4):549-559
pubmed: 31941753
Cancer Res. 2017 Apr 15;77(8):2078-2089
pubmed: 28202511
Mol Cancer Res. 2017 Jul;15(7):915-928
pubmed: 28289161
J Biol Chem. 1997 May 23;272(21):13829-34
pubmed: 9153240
Sci Transl Med. 2011 Mar 23;3(75):75ra26
pubmed: 21430269
PLoS One. 2012;7(7):e41017
pubmed: 22815900
Br J Cancer. 2019 Oct;121(9):725-737
pubmed: 31564718
Bioorg Med Chem Lett. 2016 Apr 15;26(8):1861-8
pubmed: 26968253
J Biol Chem. 2000 May 5;275(18):13842-8
pubmed: 10788507
Cell. 1998 Aug 21;94(4):491-501
pubmed: 9727492
PLoS Med. 2007 Oct;4(10):1669-79; discussion 1680
pubmed: 17973572
Apoptosis. 2009 Apr;14(4):607-23
pubmed: 19194800
JAMA Oncol. 2018 Nov 1;4(11):1527-1534
pubmed: 30073261
PLoS Med. 2007 Oct 9;4(10):e294
pubmed: 17927446